By Salem Chicago News Staff
Chicago-based investment firm William Blair on Friday announced the initiation of equity research coverage on Perspective Therapeutics Inc., a clinical-stage radiopharmaceuticals company focused on the lead-212 payload.
The coverage initiation signals institutional interest in the biotech company from one of Chicago’s established financial firms. William Blair’s equity research team regularly initiates coverage on companies across the healthcare, technology and financial services sectors.
The firm also initiated research coverage on Zentalis Pharmaceuticals Inc. on Wednesday and The Metals Royalty Company Inc. and Lyntris Inc. on Sept. 14.
William Blair was also recognized among Massachusetts’ Most Charitable Companies for a sixth consecutive year by the Boston Business Journal on Sept. 15.
The firm is headquartered in Chicago. Media inquiries can be directed to Padraic Swanton at (312) 364-5290.
